Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/134007
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Albiñana, Virginia | es_ES |
dc.contributor.author | Recio-Poveda, Lucía | es_ES |
dc.contributor.author | Zarrabeitia, Roberto | es_ES |
dc.contributor.author | Bernabéu, Carmelo | es_ES |
dc.contributor.author | Botella, Luisa María | es_ES |
dc.date.accessioned | 2016-06-23T12:52:49Z | - |
dc.date.available | 2016-06-23T12:52:49Z | - |
dc.date.issued | 2012-05-03 | - |
dc.identifier.citation | Thromb Haemost. 108(1):41-53 (2012) | es_ES |
dc.identifier.issn | 0340-6245 | - |
dc.identifier.uri | http://hdl.handle.net/10261/134007 | - |
dc.description | 28 p.-9 fig. | es_ES |
dc.description.abstract | The β-blocker propranolol, originally designed for cardiological indications (angina, cardiac arrhythmias and high blood pressure), is nowadays, considered the most efficient drug for the treatment in infantile haemangiomas (IH), a vascular tumour that affects 5–10% of all infants. However, its potential therapeutic benefits in other vascular anomalies remain to be explored. In the present work we have assessed the impact of propranolol in endothelial cell cultures to test if this drug could be used in the vascular disease hereditary haemorrhagic telangiectasia (HHT). This rare disease is the result of abnormal angiogenesis with epistaxis, mucocutaneous and gastrointestinal telangiectases, as well as arteriovenous malformations in several organs, as clinical manifestations. Mutations in Endoglin (ENG) and ACVLR1 (ALK1) genes, lead to HHT1 and HHT2, respectively. Endoglin and ALK1 are involved in the TGF-β1 signalling pathway and play a critical role for the proper development of the blood vessels. As HHT is due to a deregulation of key angiogenic factors, inhibitors of angiogenesis have been used to normalise the nasal vasculature eliminating epistaxis derived from telangiectases. Thus, the antiangiogenic properties of propranolol were tested in endothelial cells. The drug was able to decrease cellular migration and tube formation, concomitantly with reduced RNA and protein levels of ENG and ALK1. Moreover, the drug showed apoptotic effects which could explain cell death in IH. Interestingly, propranolol showed some profibrinolytic activity, decreasing PAI-1 levels. These results suggest that local administration of propranolol in the nose mucosa to control epistaxis might be a potential therapeutic approach in HHT. | es_ES |
dc.description.sponsorship | Virginia Albiñana was supported by fellowships from Fundación Ramón Areces and Real e Ilustre Colegio de Farmaceúticos de Sevilla. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Schattauer | es_ES |
dc.relation.isversionof | Postprint | es_ES |
dc.rights | openAccess | es_ES |
dc.subject | HHT | es_ES |
dc.subject | Endoglin | es_ES |
dc.subject | Epistaxis | es_ES |
dc.subject | ALK1 | es_ES |
dc.subject | Propranolol | es_ES |
dc.title | Propranolol as an antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.1160/TH11-11-0809 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | http://dx.doi.org/ 10.1160/TH11-11-0809 | es_ES |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.languageiso639-1 | en | - |
item.fulltext | With Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | open | - |
item.openairetype | artículo | - |
Aparece en las colecciones: | (CIB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Thromb.Haemos.Figuras Finales Propra_2012.pptx | Postprint | 9,08 MB | Microsoft Powerpoint XML | Visualizar/Abrir |
Thromb. Haemos.Propranolol 2012.doc | Postprint | 128,5 kB | Microsoft Word | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
44
checked on 22-abr-2024
WEB OF SCIENCETM
Citations
41
checked on 27-feb-2024
Page view(s)
308
checked on 23-abr-2024
Download(s)
321
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.